FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126501086> ?p ?o ?g. }

• W2126501086 endingPage "456" @default.
• W2126501086 startingPage "452" @default.
• W2126501086 abstract "The aim of the study was to evaluate functional and anatomical changes after intravitreal bevacizumab (Avastin) in eyes with persistent macular oedema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).Twenty-nine consecutive eyes with macular oedema secondary to BRVO (21 eyes) or CRVO (eight eyes) were included in a prospective clinical trial. Eyes were treated with three initial intravitreal bevacizumab injections of 1 mg at a monthly interval. Retreatment was based on central retinal thickness (CRT) based on optical coherence tomography. If continuous injections were indicated up to month 6, the dose was increased to 2.5 mg.After 12 months of follow-up, mean visual acuity increased from 50 letters (20/100) at baseline to 66 letters (20/50(+1); +16 letters; p<0.001) at month 12 and CRT decreased from 558 mum at baseline to 309 mum at month 12 (-249 mum; p<0.001). Patients received a mean of eight out of 13 possible injections. No drug-related systemic or ocular side effects following intravitreal bevacizumab treatment were observed. Fluorescein angiography revealed no progression of avascular areas.Intravitreal therapy using bevacizumab appears to be a safe and effective treatment in patients with macular oedema secondary to retinal vein occlusion. However, the main limitations of this treatment modality are its short-term effectiveness and high recurrence rate." @default.
• W2126501086 created "2016-06-24" @default.
• W2126501086 creator A5012927829 @default.
• W2126501086 creator A5031412911 @default.
• W2126501086 creator A5038462897 @default.
• W2126501086 creator A5053563726 @default.
• W2126501086 creator A5055824951 @default.
• W2126501086 creator A5063581584 @default.
• W2126501086 creator A5069133257 @default.
• W2126501086 creator A5091910497 @default.
• W2126501086 date "2008-12-15" @default.
• W2126501086 modified "2023-10-01" @default.
• W2126501086 title "Intravitreal bevacizumab (Avastin(R)) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial" @default.
• W2126501086 cites W1559170621 @default.
• W2126501086 cites W1564638932 @default.
• W2126501086 cites W1898187276 @default.
• W2126501086 cites W1976993504 @default.
• W2126501086 cites W1980739272 @default.
• W2126501086 cites W1989523910 @default.
• W2126501086 cites W1997624252 @default.
• W2126501086 cites W2002861350 @default.
• W2126501086 cites W2003640321 @default.
• W2126501086 cites W2015775567 @default.
• W2126501086 cites W2022621467 @default.
• W2126501086 cites W2033680298 @default.
• W2126501086 cites W2039446733 @default.
• W2126501086 cites W2054438872 @default.
• W2126501086 cites W2075820248 @default.
• W2126501086 cites W2087650196 @default.
• W2126501086 cites W2117340362 @default.
• W2126501086 cites W2133950656 @default.
• W2126501086 cites W2151081020 @default.
• W2126501086 cites W2153035067 @default.
• W2126501086 cites W2258214700 @default.
• W2126501086 cites W2324588265 @default.
• W2126501086 cites W3350394 @default.
• W2126501086 doi "https://doi.org/10.1136/bjo.2008.141085" @default.
• W2126501086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19074916" @default.
• W2126501086 hasPublicationYear "2008" @default.
• W2126501086 type Work @default.
• W2126501086 sameAs 2126501086 @default.
• W2126501086 citedByCount "204" @default.
• W2126501086 countsByYear W21265010862012 @default.
• W2126501086 countsByYear W21265010862013 @default.
• W2126501086 countsByYear W21265010862014 @default.
• W2126501086 countsByYear W21265010862015 @default.
• W2126501086 countsByYear W21265010862016 @default.
• W2126501086 countsByYear W21265010862017 @default.
• W2126501086 countsByYear W21265010862018 @default.
• W2126501086 countsByYear W21265010862019 @default.
• W2126501086 countsByYear W21265010862020 @default.
• W2126501086 countsByYear W21265010862021 @default.
• W2126501086 countsByYear W21265010862022 @default.
• W2126501086 crossrefType "journal-article" @default.
• W2126501086 hasAuthorship W2126501086A5012927829 @default.
• W2126501086 hasAuthorship W2126501086A5031412911 @default.
• W2126501086 hasAuthorship W2126501086A5038462897 @default.
• W2126501086 hasAuthorship W2126501086A5053563726 @default.
• W2126501086 hasAuthorship W2126501086A5055824951 @default.
• W2126501086 hasAuthorship W2126501086A5063581584 @default.
• W2126501086 hasAuthorship W2126501086A5069133257 @default.
• W2126501086 hasAuthorship W2126501086A5091910497 @default.
• W2126501086 hasBestOaLocation W21265010861 @default.
• W2126501086 hasConcept C118487528 @default.
• W2126501086 hasConcept C141071460 @default.
• W2126501086 hasConcept C188816634 @default.
• W2126501086 hasConcept C2776268601 @default.
• W2126501086 hasConcept C2776694085 @default.
• W2126501086 hasConcept C2777802072 @default.
• W2126501086 hasConcept C2778257484 @default.
• W2126501086 hasConcept C2778844676 @default.
• W2126501086 hasConcept C2780248432 @default.
• W2126501086 hasConcept C2780261187 @default.
• W2126501086 hasConcept C2780347916 @default.
• W2126501086 hasConcept C2780827179 @default.
• W2126501086 hasConcept C2908732032 @default.
• W2126501086 hasConcept C71924100 @default.
• W2126501086 hasConceptScore W2126501086C118487528 @default.
• W2126501086 hasConceptScore W2126501086C141071460 @default.
• W2126501086 hasConceptScore W2126501086C188816634 @default.
• W2126501086 hasConceptScore W2126501086C2776268601 @default.
• W2126501086 hasConceptScore W2126501086C2776694085 @default.
• W2126501086 hasConceptScore W2126501086C2777802072 @default.
• W2126501086 hasConceptScore W2126501086C2778257484 @default.
• W2126501086 hasConceptScore W2126501086C2778844676 @default.
• W2126501086 hasConceptScore W2126501086C2780248432 @default.
• W2126501086 hasConceptScore W2126501086C2780261187 @default.
• W2126501086 hasConceptScore W2126501086C2780347916 @default.
• W2126501086 hasConceptScore W2126501086C2780827179 @default.
• W2126501086 hasConceptScore W2126501086C2908732032 @default.
• W2126501086 hasConceptScore W2126501086C71924100 @default.
• W2126501086 hasIssue "4" @default.
• W2126501086 hasLocation W21265010861 @default.
• W2126501086 hasLocation W21265010862 @default.
• W2126501086 hasOpenAccess W2126501086 @default.
• W2126501086 hasPrimaryLocation W21265010861 @default.
• W2126501086 hasRelatedWork W2023340561 @default.
• W2126501086 hasRelatedWork W2146028782 @default.

• next